Apr 27, 2022 / 01:30PM GMT
Søren Bregenholt - Alligator Bioscience AB - CEO
Thank you and welcome to this interim report call from Alligator Bioscience. My name is Søren Bregenholt, the CEO of the Alligator Bioscience. And with me today, I have our Chief Financial Officer, Marie Svensson. Before we get into the actual call, if we could have the disclaimer, I want to remind you that during this call there will be forward-looking statements, both on the financial performance and the actual project performance of the company.
If we go to slide number 3, I just wanted to highlight some of the priorities that we -- and some of the milestones that Alligator achieved during 2021, allowing us to go into 2022 in a strong position. First of all, we initiated Phase II clinical development with our lead asset, Mitazalimab, in first-line pancreatic cancer patients in combination Folfirinox chemotherapy; Phase I assets, 1017, we reported positive biomarker data, and the intention to move -- and safety data and the intention to move forward to Phase II.
We presented several collaborations during the year
Q1 2022 Alligator Bioscience AB Earnings Call Transcript
Apr 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers